IBRX - ImmunityBio posts early-stage interim data showing potential of COVID-19 vaccine

Announcing preliminary Phase 1 data, ImmunityBio (IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against the new coronavirus variants.A single subcutaneous injection of the shot in healthy subjects has generated T cells that are reactive to the spike (S) and nucleocapsid (N) protein antigens delivered by the vaccine, the company said.By day 21, T cell responses against both S and N antigens reached levels have reached ten times higher than the pre-vaccination levels. The mean T cell levels in those inoculated with the vaccine were equivalent to patients recovered from the COVID-19 infection.However, the data are yet to be peer-reviewed and are published in the preprint server medRxiv.Targeting the S protein of the virus, the current generation of vaccines are less effective against coronavirus variants, noted, Patrick Soon-Shiong, CEO of ImmunityBio.“Our goal is to develop the

For further details see:

ImmunityBio posts early-stage interim data showing potential of COVID-19 vaccine